吴妮 | 撰文又一 | 编辑2025年行至一半,中国创新药BD交易总额已达到500亿美元,逼近2024年全年的交易额。这背后是交易数量与单笔交易金额的双增长,其中三生制药与辉瑞的合作,再次刷新了首付款新高,达到12.5亿美元。BD收入从“解一时之渴”转变为稳定的现金流。在这个过程中,中国药企还在快速成长,在传统License-in/out、newco领域已经标准化,特别是临床阶段资产交易。他们的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.